Clinical Trials Logo

Parkinsons Disease With Dementia clinical trials

View clinical trials related to Parkinsons Disease With Dementia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03608553 Active, not recruiting - Clinical trials for Parkinsons Disease With Dementia

A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia

Start date: November 26, 2018
Phase: N/A
Study type: Interventional

The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and initial efficacy of this treatment (temporary disruption of the BBB) using this ExAblate Model 4000 Type 2 System in patients with mild to moderate Parkinson´s Disease Dementia

NCT ID: NCT02954978 Active, not recruiting - Parkinson Disease Clinical Trials

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

PD Nilotinib
Start date: January 2017
Phase: Phase 2
Study type: Interventional

Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and formation of inclusions known as Lewy bodies (LBs) that primarily contain aggregated alpha-Synuclein. Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) is approved by U.S. Food and Drug Administration (FDA) and is well tolerated for CML treatment at oral doses of 600-800mg daily. Nilotinib penetrates the brain and promotes autophagic degradation of alpha-Synuclein and p-Tau, leading to survival of DA neurons and improvement of motor function in PD models. For these studies, Nilotinib (1-10mg/kg daily) was used at significantly less than the clinically approved dose (up to 1200mg daily) in CML.